Investigation of Mechanism of Drug-induced Cardiac Injury and Torsades De Pointes in Cynomolgus Monkeys

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2011 Oct 28

PMID 22029876

Citations 1

Authors

D L Misner

C Frantz

L Guo

M R Gralinski

P B Senese

J Ly

M Albassam

K L Kolaja

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Drug candidates must be thoroughly investigated for their potential cardiac side effects. During the course of routine toxicological assessment, the compound RO5657, a CCR5 antagonist, was discovered to have the rare liability of inducing torsades de pointes (polymorphic ventricular arrhythmia) in normal, healthy animals. Studies were conducted to determine the molecular mechanism of this arrhythmia.

Experimental Approach: Toxicological effects of repeat dosing were assessed in naïve monkeys. Cardiovascular effects were determined in conscious telemetry-implanted monkeys (repeat dosing) and anaesthetized instrumented dogs (single doses). Mechanistic studies were performed in guinea-pig isolated hearts and in cells recombinantly expressing human cardiac channels.

Key Results: In cynomolgus monkeys, RO5657 caused a low incidence of myocardial degeneration and a greater incidence of ECG abnormalities including prolonged QT/QTc intervals, QRS complex widening and supraventricular tachycardia. In telemetry-implanted monkeys, RO5657 induced arrhythmias, including torsades de pointes and in one instance, degeneration to fatal ventricular fibrillation. RO5657 also depressed both heart rate (HR) and blood pressure (BP), with no histological evidence of myocardial degeneration. In the anaesthetized dog and guinea-pig isolated heart studies, RO5657 induced similar cardiovascular effects. RO5657 also inhibited Kv11.1 and sodium channel currents.

Conclusions And Implications: The molecular mechanism of RO5657 is hypothesized to be due to inhibition of cardiac sodium and Kv11.1 potassium channels. These results indicate that RO5657 is arrhythymogenic due to decreased haemodynamic function (HR/BP), decreased conduction and inhibition of multiple cardiac channels, which precede and are probably the causative factors in the observed myocardial degeneration.

Citing Articles

Stem cells and stem cell-derived tissues and their use in safety assessment.

Kolaja K J Biol Chem. 2013; 289(8):4555-61.

PMID: 24362027 PMC: 3931016. DOI: 10.1074/jbc.R113.481028.

References

Valentin J . Reducing QT liability and proarrhythmic risk in drug discovery and development. Br J Pharmacol. 2010; 159(1):5-11. PMC: 2823346. DOI: 10.1111/j.1476-5381.2009.00547.x. View

Rotstein D, Gabriel S, Makra F, Filonova L, Gleason S, Brotherton-Pleiss C . Spiropiperidine CCR5 antagonists. Bioorg Med Chem Lett. 2009; 19(18):5401-6. DOI: 10.1016/j.bmcl.2009.07.122. View

Stummann T, Beilmann M, Duker G, Dumotier B, Fredriksson J, Jones R . Report and recommendations of the workshop of the European Centre for the Validation of Alternative Methods for Drug-Induced Cardiotoxicity. Cardiovasc Toxicol. 2009; 9(3):107-25. DOI: 10.1007/s12012-009-9045-3. View

Pugsley M, Curtis M . Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document. J Pharmacol Toxicol Methods. 2006; 54(2):94-8. DOI: 10.1016/j.vascn.2006.05.002. View

. International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice. Fed Regist. 2005; 70(202):61133-4. View

Abel S, Russell D, Whitlock L, Ridgway C, Nedderman A, Walker D . Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol. 2008; 65 Suppl 1:60-7. PMC: 2311408. DOI: 10.1111/j.1365-2125.2008.03137.x. View

Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M . Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005; 49(11):4721-32. PMC: 1280117. DOI: 10.1128/AAC.49.11.4721-4732.2005. View

Ly J, Shyy G, Misner D . Assessing hERG channel inhibition using PatchXpress. Clin Lab Med. 2007; 27(1):201-8. DOI: 10.1016/j.cll.2006.12.011. View

Davis J, Hackman F, Layton G, Higgins T, Sudworth D, Weissgerber G . Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. Br J Clin Pharmacol. 2008; 65 Suppl 1:68-75. PMC: 2311415. DOI: 10.1111/j.1365-2125.2008.03138.x. View

10.

Yang H, Rotstein D . Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006 - 2008. Expert Opin Ther Pat. 2010; 20(3):325-54. DOI: 10.1517/13543770903575674. View

11.

Barber C, Blakemore D, Chiva J, Eastwood R, Middleton D, Paradowski K . 1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2. Bioorg Med Chem Lett. 2009; 19(5):1499-503. DOI: 10.1016/j.bmcl.2009.01.008. View

12.

Cheng H, Incardona J . Models of torsades de pointes: effects of FPL64176, DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts. J Pharmacol Toxicol Methods. 2009; 60(2):174-84. DOI: 10.1016/j.vascn.2009.05.010. View

13.

Sugiyama A . Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol. 2008; 154(7):1528-37. PMC: 2492090. DOI: 10.1038/bjp.2008.240. View

14.

Farkas A, Nattel S . Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice. Drugs. 2010; 70(5):573-603. DOI: 10.2165/11535230-000000000-00000. View

15.

Sala M, Coppa F, Cappucciati C, Brambilla P, dAllio G, Caverzasi E . Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes. Curr Opin Investig Drugs. 2006; 7(3):256-63. View

16.

Giorgi M, Bolanos R, Gonzalez C, Di Girolamo G . QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications. Curr Drug Saf. 2010; 5(1):54-7. DOI: 10.2174/157488610789869148. View

17.

Roden D . Cellular basis of drug-induced torsades de pointes. Br J Pharmacol. 2008; 154(7):1502-7. PMC: 2492095. DOI: 10.1038/bjp.2008.238. View

18.

De Clerck F, Van de Water A, DAubioul J, Lu H, van Rossem K, Hermans A . In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity. Fundam Clin Pharmacol. 2002; 16(2):125-40. DOI: 10.1046/j.1472-8206.2002.00081.x. View

19.

Guo L, Abrams R, Babiarz J, Cohen J, Kameoka S, Sanders M . Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2011; 123(1):281-9. DOI: 10.1093/toxsci/kfr158. View

20.

Lawrence C, Pollard C, Hammond T, Valentin J . In vitro models of proarrhythmia. Br J Pharmacol. 2008; 154(7):1516-22. PMC: 2492094. DOI: 10.1038/bjp.2008.195. View